Approximately one in every ten adults is diabetic. In 2019, the global prevalence of diabetes among adults was 8.3%, and this figure is still rising, with an expected increase to 9.9% by 2030.
In 2022, there were 530,000 new cases of Type 1 Diabetes (T1D) diagnosed, of which 201,000 were patients under the age of 20.
Most individuals with Type 1 diabetes are diagnosed during childhood or adolescence, although some adults are also affected.
Risk factors for Type 1 diabetes include genetics, toxins, immune system disorders, and viral infections.
Type 1 diabetes is a disease that results in the destruction of the insulin-producing pancreatic beta cells, leading to an absolute deficiency in insulin secretion.
Most patients are diagnosed during childhood or adolescence. Complications of Type 1 diabetes, including acute ketoacidosis and chronic diabetic foot, involve other systems and organs, reducing the quality of life for patients.
How To Solve it?
Based on these considerations, we have designed a blood sugar stabilizer that can precisely control the patient's insulin concentration.
Our system primarily consists of three components:
The blood sugar concentration sensor switch we have designed can accurately sense pathological blood sugar levels and promote insulin secretion.
When the glucose concentration reaches a pathological state, the switch opens and activates a blue light.
As the blood sugar decreases and returns to a physiological state, the relevant transcription factors cannot be degraded in a short time, posing a risk of hypoglycemia. How to resolve this?
We have added a braking system that can be used when blood sugar levels decrease to inhibit insulin synthesis.